Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2022 Nov;39(11):5011-5012.
doi: 10.1007/s12325-022-02288-x.

Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Afisi S Ismaila  1   2   3 , Katrin Haeussler  4 , Alexandrosz Czira  5 , Vanita Tongbram  6 , Mia Malmenäs  7 , Jatin Agarwal  8 , Maria Nassim  4 , Marija Živković-Gojović  9 , Yunrong Shen  10 , Xinzhe Dong  11 , Maria Duarte  5 , Chris Compton  5 , Claus F Vogelmeier  12 , David M G Halpin  13
Affiliations
Published Erratum

Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Afisi S Ismaila et al. Adv Ther. 2022 Nov.
No abstract available

PubMed Disclaimer

Figures

Fig. 4
Fig. 4
Fixed effects model of mean difference in change from baseline in TDI focal score of UMEC/VI versus a dual therapy and b monotherapy at 24 weeks. Assessment of heterogeneity/inconsistency: I2 = 0%; Q = 12.60; p = 0.4793. ACL aclidinium, CFB change from baseline, CI confidence interval, FOR formoterol fumarate, FP fluticasone propionate, GLY glycopyrronium, IND indacaterol, PBO placebo, SAL salmeterol, TDI Transitional Dyspnoea Index, TIO tiotropium, UMEC umeclidinium, VI vilanterol
See this image and copyright information in PMC

Erratum for

Publication types

LinkOut - more resources